MMIP briefing paper: The fiscal benefits of establishing and retaining medicine manufacture in the UK
This paper highlights the factors which combine to make the UK one of the most competitive tax and fiscal frameworks globally for medicines manufacture and in the top tier of the G20. This is not widely recognised here in the UK or overseas and the purpose of this paper is to start to address this lack of awareness by setting out the UK proposition in a simple summary.
Chris Molloy on Mike Hoare, the RedX-Skye deal, Stablepharma’s fridge-free vaccine, MHRA quarterly numbers, ministerial responsibilities for UK life sciences and human biology-based models
The Milner Therapeutics Institute has joined the o2h Discovery Platinum Partner Programme, enabling eligible companies within its bio-incubator and wider affiliate network to access specialist drug discovery support through the o2h Kickstarter Award.
Drug Discovery 2026 returns to ExCeL London from 14–15 October to celebrate 20 years of collaboration and inclusion. Keynote programme includes presentation from Dr Sam Barrell CBE and panel discussion with Dr Anne Phelan, Dr Jason Mellad, Prof Sir Mene Pangalos and Prof Raghib Ali OBE
